Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
76. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
77. |
ECCT/21/06/01 | ACTIV-2/A5401 ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_ |
Principal Investigator(s) 1. Charles Meja Kwobah Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
78. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
View |
79. |
ECCT/24/10/03 | EDE Scanner Study A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria |
Principal Investigator(s) 1. VIDELIS Nduba 2. Berngards Ogutu Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county) 3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county) |
View |
80. |
ECCT/24/06/05 | SII-qHPV Vaccine Study A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years. |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) 2. KEMRI - CCR Nairobi (Nairobi City county) |
View |